Ayala Pharmaceuticals Inc (ADXS)

[Traderbx]

ADXS vs MERK

ADXS:
38% 12-Month Survival with ADXS screwed with FDA hold in phase 2 also (stopped recruiting additional patients)

Tumor Best Response
Overall (N = 50)
CR 1 (2)
SD 15 (30)
PD 22 (44)
NE 10 (20)

Summary:
ADXS 1 COMPLETE RESPONSE AND 15 STABLE DISEASE

----------------------------------------


MERK DATA
82 patients in the advanced cervical squamous cell cancer cohort, with 3 complete responses and 7 partial responses.1 All 10 responses were ongoing at the data cutoff. Seventeen patients had stable disease and 44 had progressive disease.

71 patients with PD-L1–positive tumors, with 3 complete responses and 7 partial responses. Fourteen patients had stable disease and 37 experienced progression. None of the 9 PD-L1–negative patients responded to treatment.

Median overall survival (OS) in all patients was 11 months (95% CI, 4-15), with a 6-month OS of 67% and a 12-month OS of 40%.

Summary:
Notice how 71 of the 82 patients are PD-L1 positive (MERK's keytruda only reacts to PD-L1 positive)

3 complete responses (compared to ADXS 1 CR but ADXS trail had fewer patients)

7 partial responses (compared to ADXS 10 patients with Stable Disease plus ADXS had fewer patients in trail)

SOURCES:
ADXS
https://www.advaxis.com/wp-content/uploads/2017/03/Advaxis_SGO2017.pdf

MERK
http://www.onclive.com/web-exclusives/fda-grants-pembrolizumab-priority-review-in-cervical-cancer